DE202014011287U1 - SC-ß Zellen und Zusammensetzungen zur Erzeugung der Zellen - Google Patents

SC-ß Zellen und Zusammensetzungen zur Erzeugung der Zellen Download PDF

Info

Publication number
DE202014011287U1
DE202014011287U1 DE202014011287.8U DE202014011287U DE202014011287U1 DE 202014011287 U1 DE202014011287 U1 DE 202014011287U1 DE 202014011287 U DE202014011287 U DE 202014011287U DE 202014011287 U1 DE202014011287 U1 DE 202014011287U1
Authority
DE
Germany
Prior art keywords
cells
cell
positive
insulin
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE202014011287.8U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of DE202014011287U1 publication Critical patent/DE202014011287U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/375—Thyroid stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE202014011287.8U 2013-06-11 2014-06-11 SC-ß Zellen und Zusammensetzungen zur Erzeugung der Zellen Expired - Lifetime DE202014011287U1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361833898P 2013-06-11 2013-06-11
US61/833,898 2013-06-11
US201461972212P 2014-03-28 2014-03-28
US61/972,212 2014-03-28

Publications (1)

Publication Number Publication Date
DE202014011287U1 true DE202014011287U1 (de) 2019-02-06

Family

ID=52022750

Family Applications (2)

Application Number Title Priority Date Filing Date
DE202014011287.8U Expired - Lifetime DE202014011287U1 (de) 2013-06-11 2014-06-11 SC-ß Zellen und Zusammensetzungen zur Erzeugung der Zellen
DE112014002780.4T Active DE112014002780B4 (de) 2013-06-11 2014-06-11 SC-ß-Zellen und Zusammensetzungen und Verfahren zur Erzeugung der Zellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE112014002780.4T Active DE112014002780B4 (de) 2013-06-11 2014-06-11 SC-ß-Zellen und Zusammensetzungen und Verfahren zur Erzeugung der Zellen

Country Status (17)

Country Link
US (16) US20170029778A1 (https=)
EP (4) EP4461806A3 (https=)
JP (8) JP6514689B2 (https=)
KR (12) KR102631225B1 (https=)
CN (6) CN120796168A (https=)
AU (7) AU2014284677B2 (https=)
BR (2) BR112015030946A8 (https=)
CA (2) CA2915091A1 (https=)
DE (2) DE202014011287U1 (https=)
DK (1) DK3008168T3 (https=)
GB (3) GB2531952C (https=)
HK (1) HK1257187B (https=)
MX (2) MX2015017103A (https=)
PH (1) PH12015502767A1 (https=)
RU (2) RU2016100219A (https=)
SG (3) SG10201710218RA (https=)
WO (2) WO2015002724A2 (https=)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2185693T3 (da) 2007-07-31 2019-09-23 Lifescan Inc Differentiering af humane embryoniske stamceller
CA2954431C (en) 2007-11-27 2021-08-24 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
FI2794857T3 (fi) 2011-12-22 2026-03-25 Janssen Biotech Inc Ihmisen alkion kantasolujen erilaistaminen yksittäisiksi hormonaalisiksi insuliinipositiivisiksi soluiksi
DK2938723T3 (da) 2012-12-31 2023-02-20 Janssen Biotech Inc Differentiering af humane embryonale stamceller til pancreatiske endokrine celler under anvendelse af hb9-regulatorer
ES2924479T3 (es) 2013-04-08 2022-10-07 Harvard College Composiciones para rejuvenecer las células madre del músculo esquelético
CN120796168A (zh) 2013-06-11 2025-10-17 哈佛学院校长同事会 SC-β细胞以及用于产生其的组合物和方法
WO2015175307A1 (en) 2014-05-16 2015-11-19 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
WO2016100921A1 (en) * 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
EP3234110B1 (en) 2014-12-18 2024-02-28 President and Fellows of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF
US10196613B2 (en) 2014-12-19 2019-02-05 Regeneron Pharmaceuticals, Inc. Stem cells for modeling type 2 diabetes
EP3286563B1 (en) * 2015-04-23 2022-11-02 The Regents of The University of California Controlled induction of human pancreatic progenitors produces functional beta-like cells
EP3285572B1 (en) * 2015-04-24 2020-12-02 University of Copenhagen Method for production of insulin-producing cells
EP3819372A3 (en) * 2015-04-24 2021-10-06 University of Copenhagen Isolation of bona fide pancreatic progenitor cells
EP3328404A4 (en) * 2015-07-27 2018-12-26 The Regents of The University of California Methods and compositions for producing pancreatic beta cells
EP3369811B1 (en) * 2015-10-29 2025-09-03 Juntendo Educational Foundation Method for producing pancreatic endocrine cells, and transdifferentiation agent
US11116777B2 (en) 2015-11-10 2021-09-14 City Of Hope Conditioning regimens and methods for inducing mixed chimerism
WO2017116569A1 (en) * 2015-12-31 2017-07-06 City Of Hope Methods for treating diabetes
CA3010799A1 (en) 2016-01-06 2017-07-13 President And Fellows Of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
US20190018000A1 (en) 2016-01-12 2019-01-17 Cedars-Sinai Medical Center A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
EP3411470A4 (en) 2016-02-01 2019-10-09 Emulate, Inc. SYSTEMS AND METHOD FOR BREEDING DARM CELLS IN MICROFLUIDIC DEVICES
CN108699515A (zh) * 2016-02-24 2018-10-23 诺和诺德股份有限公司 由人多能干细胞衍生的内分泌祖细胞生成功能性β细胞
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US20190060371A1 (en) * 2016-03-02 2019-02-28 Frequency Therapeutics, Inc. Methods for controlled proliferation of vestibular stem cells / generating inner ear hair cells using wnt and tgfbeta-inhibition
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
ES3002713T3 (en) 2016-04-08 2025-03-07 Univ California Production of fully functional mature beta cells from human pancreatic progenitors
WO2017214465A1 (en) * 2016-06-09 2017-12-14 Georgetown University Process for continuous cell culture of islet cells
MD4194548T2 (ro) 2016-06-21 2026-02-28 Janssen Biotech Inc Generarea de celule beta funcționale derivate din celule stem pluripotente umane care posedă respirație mitocondrială dependentă - de glucoză și răspuns la secreția de insulină în două faze
US12338462B2 (en) 2016-11-16 2025-06-24 Allele Biotechnology And Pharmaceuticals, Inc. Induction of pancreatic beta cells by stem cell differentiation with RNA
KR102586507B1 (ko) 2016-11-16 2023-10-11 알렐 바이오테크놀로지 앤 파마슈티칼스, 인크. Ｒｎａ를 사용한 줄기 세포 분화에 의한 간세포의 유도
US11913022B2 (en) 2017-01-25 2024-02-27 Cedars-Sinai Medical Center In vitro induction of mammary-like differentiation from human pluripotent stem cells
KR101745297B1 (ko) 2017-02-02 2017-06-09 경북대학교 산학협력단 비만 진단용 조성물 및 이의 용도
US11767513B2 (en) 2017-03-14 2023-09-26 Cedars-Sinai Medical Center Neuromuscular junction
WO2018176001A2 (en) 2017-03-24 2018-09-27 Cedars-Sinai Medical Center Methods and compositions for production of fallopian tube epithelium
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN111565707A (zh) 2017-06-14 2020-08-21 森玛治疗公司 用于递送治疗物的装置和方法
US20210355448A1 (en) * 2017-06-26 2021-11-18 City Of Hope Methods of islet cell culture
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
CN111246864A (zh) * 2017-07-21 2020-06-05 森玛治疗公司 干细胞衍生的胰腺β细胞的重聚
CA2983845C (en) 2017-10-26 2024-01-30 University Of Copenhagen Generation of glucose-responsive beta cells
EP3710021A4 (en) * 2017-11-15 2021-08-11 Semma Therapeutics, Inc. ISLAND CELL MANUFACTURING COMPOSITIONS AND METHOD OF USE
EP3758719A4 (en) * 2018-03-02 2021-12-08 Vertex Pharmaceuticals Inc. METHODS FOR IMPROVING THE DIFFERENTIATION OF STEM CELLS INTO BETA CELLS
EP4700387A2 (en) 2018-03-23 2026-02-25 Cedars-Sinai Medical Center Methods of use of islet cells
WO2019195800A1 (en) 2018-04-06 2019-10-10 Cedars-Sinai Medical Center Novel differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
WO2019195798A1 (en) 2018-04-06 2019-10-10 Cedars-Sinai Medical Center Human pluripotent stem cell derived neurodegenerative disease models on a microfluidic chip
EP3787613B1 (en) 2018-04-30 2026-03-11 Cedars-Sinai Medical Center Pkc activation for use in treating early onset sporadic parkinson's disease
US12421499B2 (en) 2018-05-11 2025-09-23 Cornell University Method of differentiation of human pluripotent stem cells to monohormonal cells
WO2020033879A1 (en) 2018-08-10 2020-02-13 Semma Therapeutics, Inc. Stem cell derived islet differentiation
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
WO2020043292A1 (en) * 2018-08-30 2020-03-05 Novo Nordisk A/S Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
US12097239B2 (en) 2018-09-21 2024-09-24 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching MRNA coding for secreted proteins
WO2020069515A1 (en) * 2018-09-28 2020-04-02 Memorial Sloan-Kettering Cancer Center Stem cell-derived human microglial cells, methods of making and methods of use
ES3062949T3 (en) * 2018-10-15 2026-04-14 Evia Life Sciences Inc Method for producing stem/precursor cells, by using low molecular weight compound, from cells derived from endodermal tissue or organ
KR102115960B1 (ko) * 2018-11-28 2020-05-27 송미연 인간 중간엽 줄기세포를 갑상선 호르몬 분비세포로 분화 방법
WO2020206046A1 (en) 2019-04-01 2020-10-08 The Broad Institute, Inc. Methods and compositions for cell therapy
US20220177849A1 (en) * 2019-04-08 2022-06-09 Novo Nordisk A/S Generation of pancreatic endoderm from stem cell derived definitive endoderm
US20220411759A1 (en) 2019-05-21 2022-12-29 President And Fellows Of Harvard College Endocrine differentiation-inducing molecule
KR102167257B1 (ko) * 2019-05-28 2020-10-19 부산대학교 산학협력단 토마티딘 처리를 통한 줄기세포의 성숙화된 심근세포로의 분화유도 촉진 방법
CN114173837A (zh) 2019-05-31 2022-03-11 W.L.戈尔及同仁股份有限公司 生物相容性膜复合材料
EP3976236A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates Inc. A biocompatible membrane composite
EP3975926A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates, Inc. A biocompatible membrane composite
CA3139292C (en) 2019-05-31 2025-06-10 Viacyte, Inc. CELL ENCAPSULATION DEVICES WITH REGULATED OXYGEN DIFFUSION DISTANCES
US20220275329A1 (en) * 2019-06-06 2022-09-01 President And Fellows Of Harvard College Compositions and methods for maturing stem cell-derived beta cells
CA3144948A1 (en) 2019-06-25 2020-12-30 Vertex Pharmaceuticals Incorporated Enhanced differentiation of beta cells
WO2021030424A1 (en) * 2019-08-13 2021-02-18 Semma Therapeutics, Inc. Pancreatic differentiation
US10740609B1 (en) 2019-08-30 2020-08-11 Numerica Corporation System and method for space object detection in daytime sky images
PH12022550542A1 (en) 2019-09-05 2023-03-20 Crispr Therapeutics Ag Universal donor cells
CA3150235A1 (en) 2019-09-05 2021-03-11 Alireza Rezania Universal donor cells
AU2020361709A1 (en) * 2019-10-10 2022-05-26 The Regents Of The University Of Colorado, A Body Corporate Use of ENTPD3 for identification, isolation, and enhancing mature stem cell derived insulin-producing cells
WO2021102305A1 (en) * 2019-11-20 2021-05-27 Washington University Methods and compositions for generating functionally mature beta cells and uses thereof
WO2021167703A1 (en) 2020-02-19 2021-08-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof
CN111269875B (zh) * 2020-03-24 2022-04-08 山东兴瑞生物科技有限公司 一种利用自体免疫细胞定向分化为胰岛细胞的方法
WO2021212044A1 (en) * 2020-04-16 2021-10-21 Washington University Methods and compositions for improving sc-beta cells or enhancing their utility
US12473537B2 (en) 2020-06-16 2025-11-18 The Broad Institute, Inc. Three-dimensional cell culture, devices, and use thereof
AU2021315814A1 (en) * 2020-07-31 2023-03-02 Vertex Pharmaceuticals Incorporated In vitro differentiation of pancreatic endocrine cells
WO2022026932A2 (en) 2020-07-31 2022-02-03 Vertex Pharmaceuticals Incorporated Differentiation of pancreatic endocrine cells
WO2022144855A1 (en) 2020-12-31 2022-07-07 Crispr Therapeutics Ag Universal donor cells
CN112980771B (zh) * 2021-03-05 2023-12-19 贝康医学科技有限公司 一种制备胰腺beta细胞的方法及其应用
CN112961823B (zh) * 2021-03-19 2024-01-23 上海爱萨尔生物科技有限公司 一种诱导多能干细胞定向分化制备胰岛β细胞的培养液
CN113046299B (zh) * 2021-03-19 2024-06-28 上海爱萨尔生物科技有限公司 一种诱导多能干细胞定向分化制备胰岛β细胞的添加剂
CN112980774B (zh) * 2021-03-19 2022-04-01 上海爱萨尔生物科技有限公司 一种诱导多能干细胞定向分化制备胰岛β细胞的培养方法
CN113234664B (zh) * 2021-05-11 2024-05-10 澳门大学 一种胰腺祖细胞的制备方法及其应用
US20220403340A1 (en) * 2021-06-11 2022-12-22 Washington University Media for cryopreserved cells and methods of making and using same
WO2023278382A1 (en) 2021-06-29 2023-01-05 Staffan Holmin Endoluminal delivery cannula
US20240393320A1 (en) 2021-09-21 2024-11-28 Okinawa Institute Of Science And Technology School Corporation Platforms for drug tests against synucleinopathy using human brain organoids
JP2024540987A (ja) 2021-10-21 2024-11-06 バーテックス ファーマシューティカルズ インコーポレイテッド 低免疫細胞
WO2023072170A1 (en) * 2021-10-28 2023-05-04 Sunshine Lake Pharma Co., Ltd. A METHOD FOR PROMOTING THE DIFFERENTIATION OF STEM CELLS INTO FUNCTIONALLY MATURE ISLET β CELLS AND USE THEREOF
CA3232971A1 (en) 2021-11-01 2023-05-04 George Harb Stem cell derived pancreatic islet differentiation
IL313150A (en) * 2021-11-30 2024-07-01 Hangzhou Reprogenix Bioscience Inc Method of generating functional islets from pluripotent stem cells
WO2023150493A2 (en) * 2022-02-01 2023-08-10 Vertex Pharmaceuticals Incorporated Cell therapy for diabetes
US12435312B2 (en) 2022-02-28 2025-10-07 Brown University Quantifying cell-derived changes in collagen synthesis, alignment, and mechanics in a 3D connective tissue model
JP2025512066A (ja) 2022-04-15 2025-04-16 スマートセラ ソリューションズ エービー エキソソームを介したｍＲＮＡ剤の送達のための組成物及び方法
US20250367240A1 (en) * 2022-06-03 2025-12-04 Cornell University Derivation of glucose-responsive insulin-secreting cells and organoids from human stomach cells and their use to treat diabetes
EP4608977A1 (en) * 2022-10-28 2025-09-03 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for accelerated production of thymic cells from pluripotent stem cells
WO2024151541A1 (en) * 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024151804A2 (en) * 2023-01-11 2024-07-18 Mayo Foundation For Medical Education And Research Methods and materials for generating stem cell-derived endocrine cell types
CN120693152A (zh) 2023-02-14 2025-09-23 沃泰克斯药物股份有限公司 包括免疫调节化合物的大囊化装置
EP4716541A2 (en) 2023-05-22 2026-04-01 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
US20250057880A1 (en) * 2023-07-28 2025-02-20 Vertex Pharmaceuticals Incorporated Cell therapy for diabetes
CN117672411B (zh) * 2023-12-05 2024-05-14 首都医科大学附属北京世纪坛医院 一种中药成分的Hormesis效应研究方法及中药成分小檗碱的应用
WO2025235400A1 (en) * 2024-05-06 2025-11-13 Vertex Pharmaceuticals Incorporated Novel islet potency assay
CN121109289A (zh) * 2025-08-31 2025-12-12 瑞吉维思生物科技(上海)有限公司 高效维持胰岛β细胞身份的胰岛类器官及其制法和应用

Citations (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US130A (en) 1837-02-16 Improvement in metallic solutions for the preservation of timber
US6774A (en) 1849-10-09 Improved jointed center-board
US3532709A (en) 1965-10-01 1970-10-06 Bayer Ag Novel poly-n-oxides and their production
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4378016A (en) 1981-07-15 1983-03-29 Biotek, Inc. Artificial endocrine gland containing hormone-producing cells
US4391909A (en) 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US5674289A (en) 1992-07-30 1997-10-07 The University Of Toledo Bioartificial pancreas
WO1998014592A2 (en) 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
WO1999020741A1 (en) 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US6023009A (en) 1996-02-23 2000-02-08 Circe Biomedical, Inc. Artificial pancreas
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6187991B1 (en) 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
WO2001051610A1 (en) 2000-01-14 2001-07-19 Bresagen Limited Ectoderm cell production
WO2001051616A2 (en) 2000-01-11 2001-07-19 Geron Corporation Techniques for growth and differentiation of human pluripotent stem cells
US20020018221A1 (en) 2000-07-13 2002-02-14 Hikmet Senay Method and system for allowing an on-line user to selectively customize a document for printing in a single batch process
WO2003020920A1 (en) 2001-09-05 2003-03-13 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US20030224411A1 (en) 2003-03-13 2003-12-04 Stanton Lawrence W. Genes that are up- or down-regulated during differentiation of human embryonic stem cells
US20050158853A1 (en) 2003-12-23 2005-07-21 D' Amour Kevin A. Definitive endoderm
US20050260749A1 (en) 2004-04-01 2005-11-24 Jon Odorico Differentiation of stem cells to endoderm and pancreatic lineage
US20060003446A1 (en) 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
US20060003313A1 (en) 2003-12-23 2006-01-05 D Amour Kevin A Methods for identifying factors for differentiating definitive endoderm
US7049296B2 (en) 2000-03-03 2006-05-23 Merck Sharp & Dohme Ltd. Gamma-secretase inhibitors
US7084246B2 (en) 2003-04-17 2006-08-01 Molecular Logix, Inc. Epidermal growth factor agonists
US20070000781A1 (en) 2003-01-24 2007-01-04 Rensselaer Polytechnic Institute Enzyme immobilization for electroosmotic flow
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US20070142376A1 (en) 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
WO2008121877A2 (en) 2007-04-02 2008-10-09 Institute For Oneworld Health Cftr inhibitor compounds and uses thereof
US20090155218A1 (en) 2004-03-10 2009-06-18 Alberto Hayek Compositions and methods for growth of embryonic stem cells
US20090186076A1 (en) 2006-02-01 2009-07-23 Kazunori Kataoka Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent
US20100267731A1 (en) 2009-04-17 2010-10-21 Summa Health Systems, LLC Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
US7888332B2 (en) 2004-03-30 2011-02-15 The Regents Of The University Of California Hydrazide-containing CFTR inhibitor compounds and uses thereof
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
US8247531B2 (en) 2006-03-20 2012-08-21 Cochran Jennifer R Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000084A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013052700A1 (en) 2011-10-04 2013-04-11 The Brigham And Women's Hospital, Inc. Novel sulfonamides
WO2013071282A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
WO2013169576A1 (en) 2012-05-08 2013-11-14 Merck Sharp & Dohme Corp. Permeable glycosidase inhibitors and uses thereof
WO2013166654A1 (en) 2012-05-08 2013-11-14 Merck Sharp & Dohme Corp. Permeable glycosidase inhibitors and uses thereof

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US7018419B2 (en) 1994-05-20 2006-03-28 Spielberg Theodore E Microporous encapsulated endocrine cell disks, biconcave disks and multidimpled chambers for hormonal replacement
EP0822834A4 (en) * 1995-04-07 2002-09-18 Einstein Coll Med RECOMBINANT (BETA) CELL AND ITS USE
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
WO2001088104A2 (en) 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AU2002213143A1 (en) 2000-10-12 2002-04-22 Institute Of Materials Research And Engineering Non-disruptive three-dimensional culture and harvest system for anchorage-dependent cells
US20040060568A1 (en) 2000-10-13 2004-04-01 Henryk Dudek Hedgehog antagonists, methods and uses related thereto
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
EP1366148A2 (en) 2001-01-24 2003-12-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Differentiation of stem cells to pancreatic endocrine cells
EP1393066A4 (en) 2001-05-15 2006-01-25 Rappaport Family Inst For Res INSULIN-PRODUCING CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS
WO2003014313A2 (en) 2001-08-06 2003-02-20 Bresagen, Ltd. Alternative compositions and methods for the culture of stem cells
CA2463914A1 (en) 2001-10-18 2003-04-24 Ixion Biotechnology, Inc. Conversion of liver stem and progenitor cells to pancreatic functional cells
US20030077256A1 (en) 2001-10-19 2003-04-24 Paul Czernichow Pancreas regeneration using embryonic pancreatic cells
US7157278B2 (en) 2001-12-04 2007-01-02 Organogenesis, Inc. Cultured cells from pancreatic islets
IL162130A0 (en) 2001-12-07 2005-11-20 Robarts Res Inst Hematopoietic cells from human embryonic stem cells
KR100930139B1 (ko) 2001-12-07 2009-12-07 사이토리 테라퓨틱스, 인크. 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법
IL162131A0 (en) 2001-12-07 2005-11-20 Geron Corp Islet cells from human embryonic stem cells
JP2006506047A (ja) * 2002-05-28 2006-02-23 ノボセル インコーポレイテッド インスリン産生細胞のための方法、成分並びに成長および分化因子
WO2003102171A1 (en) 2002-05-28 2003-12-11 Becton, Dickinson And Company Expansion and transdifferentiation of human acinar cells
US20060040385A1 (en) 2002-12-05 2006-02-23 Technion Research & Development Foundation Ltd. Cultured human pancreatic islets, and uses thereof
WO2004058764A1 (en) 2002-12-27 2004-07-15 Bayer Healthcare Ag 4-phenyl-pyrimido [4,5-b] indole derivatives
US8586357B2 (en) 2003-12-23 2013-11-19 Viacyte, Inc. Markers of definitive endoderm
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US7625753B2 (en) 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
JP2005278501A (ja) * 2004-03-30 2005-10-13 Asahi Kasei Corp 膵幹様細胞の分化誘導方法
EP2377922B1 (en) 2004-04-27 2020-04-08 Viacyte, Inc. PDX1 expressing endoderm
GB2431165B (en) 2004-07-13 2009-04-01 Geron Corp Medium for growing human embryonic stem cells
US8187878B2 (en) 2004-08-13 2012-05-29 University Of Georgia Research Foundation, Inc. Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
WO2006083782A2 (en) 2005-01-31 2006-08-10 Es Cell International Pte Ltd. Directed differentiation of embryonic stem cells and uses thereof
CN103356706B (zh) 2005-03-31 2016-01-20 斯丹姆涅恩有限公司 促进无疤愈合或改善皮肤外观的美容制剂
JP5560393B2 (ja) 2005-06-22 2014-07-23 アステリアス バイオセラピューティクス インコーポレイテッド 心筋細胞系列細胞への霊長類多能性幹細胞の分化
JP5560391B2 (ja) 2005-06-22 2014-07-23 アステリアス バイオセラピューティクス インコーポレイテッド ヒト胚性幹細胞の懸濁培養法
AU2006270066A1 (en) 2005-07-19 2007-01-25 University Of Tennessee Research Foundation LPA2 receptor agonist inhibitors of CFTR
WO2007051038A2 (en) 2005-10-27 2007-05-03 Cythera, Inc. Pdx1-expressing dorsal and ventral foregut endoderm
WO2007075807A2 (en) 2005-12-20 2007-07-05 Es Cell International Pte Ltd. Methods for the directed differentiation of embryonic stem cell
AU2007207434B2 (en) 2006-01-20 2012-04-05 Reneuron, Inc. Method of improving cell proliferation of pancreatic progenitor cells in a pancreatic cell culture
EP1989297B1 (en) 2006-02-13 2015-03-25 The Board of Trustees of The Leland Stanford Junior University Blockade of gamma-secretase activity to promote myelination by oligodendrocytes
SG170021A1 (en) 2006-02-23 2011-04-29 Novocell Inc Compositions and methods useful for culturing differentiable cells
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
JP6110048B2 (ja) * 2006-03-02 2017-04-05 ヴィアサイト，インコーポレイテッド 内分泌前駆細胞、膵臓ホルモン発現細胞及びそれらの製造方法
AU2007244675A1 (en) 2006-04-28 2007-11-08 Lifescan, Inc. Differentiation of human embryonic stem cells
US7964402B2 (en) 2006-05-25 2011-06-21 Sanford-Burnham Medical Research Institute Methods for culture and production of single cell populations of human embryonic stem cells
US20090298169A1 (en) * 2006-06-02 2009-12-03 The University Of Georgia Research Foundation Pancreatic and Liver Endoderm Cells and Tissue by Differentiation of Definitive Endoderm Cells Obtained from Human Embryonic Stems
US8415153B2 (en) 2006-06-19 2013-04-09 Geron Corporation Differentiation and enrichment of islet-like cells from human pluripotent stem cells
AU2007277364B2 (en) 2006-07-26 2010-08-12 Viacyte, Inc. Methods of producing pancreatic hormones
US8361489B2 (en) 2006-08-29 2013-01-29 The University Of Akron Implantable devices for producing insulin
EP2118309B1 (en) * 2006-12-29 2015-01-28 The Regents of the University of Colorado, a body corporate Diagnostic and therapeutic target for autoimmune diseases and uses thereof
CA2678870C (en) * 2007-02-21 2017-07-11 Sarl Endocells Human pancreatic beta cell lines for diagnostic of diabetes
EP3957716A1 (en) 2007-07-18 2022-02-23 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
DK2185693T3 (da) 2007-07-31 2019-09-23 Lifescan Inc Differentiering af humane embryoniske stamceller
CN101970458B (zh) 2007-08-09 2013-08-28 株式会社益力多本社 新型γ分泌酶抑制剂
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8623650B2 (en) 2007-10-19 2014-01-07 Viacyte, Inc. Methods and compositions for feeder-free pluripotent stem cell media containing human serum
CA2954431C (en) 2007-11-27 2021-08-24 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
SG154367A1 (en) * 2008-01-31 2009-08-28 Es Cell Int Pte Ltd Method of differentiating stem cells
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
AU2008355123B2 (en) 2008-04-21 2014-12-04 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
US8728812B2 (en) 2008-04-22 2014-05-20 President And Fellows Of Harvard College Compositions and methods for promoting the generation of PDX1+ pancreatic cells
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US20090298178A1 (en) 2008-06-03 2009-12-03 D Amour Kevin Allen Growth factors for production of definitive endoderm
EP2942392B1 (en) 2008-06-30 2018-10-03 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
WO2010022395A2 (en) * 2008-08-22 2010-02-25 President And Fellows Of Harvard College Methods of reprogramming cells
EP2350265B1 (en) * 2008-10-31 2019-04-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
US9234178B2 (en) * 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
JP2012508584A (ja) 2008-11-14 2012-04-12 ヴィアサイト，インコーポレイテッド ヒト多能性幹細胞由来膵臓細胞のカプセル化
KR101687344B1 (ko) 2008-11-20 2016-12-16 얀센 바이오테크 인코포레이티드 평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US8507274B2 (en) 2009-02-06 2013-08-13 President And Fellows Of Harvard College Compositions and methods for promoting the generation of definitive endoderm
EP2421957B1 (en) * 2009-04-22 2020-11-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
CN107603943B (zh) 2009-04-27 2019-10-11 威盛细胞有限公司 支持多能细胞生长的小分子和其方法
WO2010135639A2 (en) * 2009-05-21 2010-11-25 Joslin Diabetes Center, Inc. Compositions and methods for promoting beta cell maturity
US8785184B2 (en) * 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
CN103952372B (zh) 2009-07-20 2016-10-05 詹森生物科技公司 人胚胎干细胞的分化
PL2494035T3 (pl) * 2009-10-29 2018-07-31 Janssen Biotech, Inc. Pluripotencjalne komórki macierzyste
SG10201408552YA (en) 2009-12-23 2015-02-27 Janssen Biotech Inc Differentiation of human embryonic stem cells
CA2785966C (en) * 2009-12-29 2020-10-27 Takeda Pharmaceutical Company Limited Method for manufacturing pancreatic-hormone-producing cells
PH12012501686A1 (en) * 2010-03-01 2020-10-19 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
WO2011128897A1 (en) 2010-04-12 2011-10-20 Technion Research & Development Foundation Ltd. Populations of pancreatic progenitor cells and methods of isolating and using same
EP2563908B1 (en) 2010-04-25 2019-01-09 Icahn School of Medicine at Mount Sinai Generation of anterior foregut endoderm from pluripotent cells
RU2587634C2 (ru) 2010-05-12 2016-06-20 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
KR101877077B1 (ko) * 2010-08-09 2018-07-10 다케다 야쿠힌 고교 가부시키가이샤 췌호르몬-생성 세포의 제조 방법
KR20190027969A (ko) * 2010-08-12 2019-03-15 얀센 바이오테크 인코포레이티드 췌장 내분비 전구 세포를 이용한 당뇨병의 치료
GB201014169D0 (en) 2010-08-25 2010-10-06 Cambridge Entpr Ltd In vitro hepatic differentiation
CN103154237B (zh) 2010-08-31 2016-03-16 詹森生物科技公司 多能干细胞的分化
EP3372672A1 (en) 2010-08-31 2018-09-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
PL2853589T3 (pl) 2010-08-31 2018-05-30 Janssen Biotech, Inc Różnicowanie ludzkich zarodkowych komórek macierzystych
US20120135015A1 (en) 2010-09-28 2012-05-31 Baylor Research Institute Induction of Pancreatic Stem Cells by Transient Overexpression of Reprogramming Factors and PDX1 Selection
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
US20120270890A1 (en) 2011-04-22 2012-10-25 Cheng-Ho Chung Methods of Pancreatic Beta Cell Regeneration
WO2013018851A1 (ja) 2011-08-02 2013-02-07 独立行政法人国立がん研究センター 誘導肝幹細胞から肝分化誘導する方法及び誘導肝前駆細胞
DK2768948T3 (en) * 2011-10-18 2017-08-14 Univercell Biosolutions PREPARATION OF A HUMAN BETA CELL LINE FROM AN EARLY POSTNATAL ARGUMENT
FI2794857T3 (fi) * 2011-12-22 2026-03-25 Janssen Biotech Inc Ihmisen alkion kantasolujen erilaistaminen yksittäisiksi hormonaalisiksi insuliinipositiivisiksi soluiksi
BR112014027783A2 (pt) 2012-05-07 2017-06-27 Janssen Biotech Inc diferenciação de células-tronco embrionárias humanas em endoderma pancreático
EP3450544A1 (en) 2012-06-08 2019-03-06 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endodrine cells
EP2861723A4 (en) 2012-06-14 2016-01-20 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYONAL STEM CELLS IN ENDOCRINE PANCREAS CELLS
CN104903440B (zh) 2012-09-03 2018-04-06 诺和诺德股份有限公司 使用小分子从多能干细胞产生胰内胚层
DK2938723T3 (da) * 2012-12-31 2023-02-20 Janssen Biotech Inc Differentiering af humane embryonale stamceller til pancreatiske endokrine celler under anvendelse af hb9-regulatorer
ES2837763T3 (es) * 2012-12-31 2021-07-01 Janssen Biotech Inc Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
BR112015015714A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
US11920160B2 (en) 2013-02-22 2024-03-05 Cedars-Sinai Medical Center Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells
US20140287944A1 (en) 2013-02-26 2014-09-25 President And Fellows Of Harvard College Markers for functionally mature beta-cells and methods of using the same
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
US20140329704A1 (en) 2013-03-28 2014-11-06 President And Fellows Of Harvard College Markers for mature beta-cells and methods of using the same
CN120796168A (zh) 2013-06-11 2025-10-17 哈佛学院校长同事会 SC-β细胞以及用于产生其的组合物和方法
CN105683361B (zh) 2013-08-30 2021-04-02 诺和诺德股份有限公司 使用小分子从人多能干细胞产生内分泌祖细胞
WO2015175307A1 (en) * 2014-05-16 2015-11-19 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
SG10201801654RA (en) 2014-05-28 2018-04-27 Childrens Hospital Med Ct Methods and systems for converting precursor cells into gastric tissues through directed differentiation
EP3178924B1 (en) 2014-08-04 2019-12-25 Takeda Pharmaceutical Company Limited Method for proliferation of pancreatic progenitor cells
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
WO2016100925A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED β CELLS AND USES THEREOF
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
EP3234110B1 (en) 2014-12-18 2024-02-28 President and Fellows of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF
WO2016100921A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
US9974784B2 (en) 2015-01-21 2018-05-22 The Texas A&M University System Inhibitors of activin-like receptor kinases
CN108699515A (zh) 2016-02-24 2018-10-23 诺和诺德股份有限公司 由人多能干细胞衍生的内分泌祖细胞生成功能性β细胞

Patent Citations (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774A (en) 1849-10-09 Improved jointed center-board
US130A (en) 1837-02-16 Improvement in metallic solutions for the preservation of timber
US3532709A (en) 1965-10-01 1970-10-06 Bayer Ag Novel poly-n-oxides and their production
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4391909A (en) 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4378016A (en) 1981-07-15 1983-03-29 Biotek, Inc. Artificial endocrine gland containing hormone-producing cells
US5674289A (en) 1992-07-30 1997-10-07 The University Of Toledo Bioartificial pancreas
US6200806B1 (en) 1995-01-20 2001-03-13 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6187991B1 (en) 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
US6023009A (en) 1996-02-23 2000-02-08 Circe Biomedical, Inc. Artificial pancreas
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
WO1998014592A2 (en) 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US6235970B1 (en) 1997-01-10 2001-05-22 University Of Massachusetts, Amherst Campus CICM cells and non-human mammalian embryos prepared by nuclear transfer of a proliferating differentiated cell or its nucleus
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
WO1999020741A1 (en) 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
WO2001051616A2 (en) 2000-01-11 2001-07-19 Geron Corporation Techniques for growth and differentiation of human pluripotent stem cells
WO2001051610A1 (en) 2000-01-14 2001-07-19 Bresagen Limited Ectoderm cell production
US7049296B2 (en) 2000-03-03 2006-05-23 Merck Sharp & Dohme Ltd. Gamma-secretase inhibitors
US20020018221A1 (en) 2000-07-13 2002-02-14 Hikmet Senay Method and system for allowing an on-line user to selectively customize a document for printing in a single batch process
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
WO2003020920A1 (en) 2001-09-05 2003-03-13 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
WO2003024215A1 (en) 2001-09-14 2003-03-27 Macropore Biosurgery, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US20060003446A1 (en) 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
US20070000781A1 (en) 2003-01-24 2007-01-04 Rensselaer Polytechnic Institute Enzyme immobilization for electroosmotic flow
US20030224411A1 (en) 2003-03-13 2003-12-04 Stanton Lawrence W. Genes that are up- or down-regulated during differentiation of human embryonic stem cells
US7084246B2 (en) 2003-04-17 2006-08-01 Molecular Logix, Inc. Epidermal growth factor agonists
US20050158853A1 (en) 2003-12-23 2005-07-21 D' Amour Kevin A. Definitive endoderm
US20060003313A1 (en) 2003-12-23 2006-01-05 D Amour Kevin A Methods for identifying factors for differentiating definitive endoderm
US20090155218A1 (en) 2004-03-10 2009-06-18 Alberto Hayek Compositions and methods for growth of embryonic stem cells
US7888332B2 (en) 2004-03-30 2011-02-15 The Regents Of The University Of California Hydrazide-containing CFTR inhibitor compounds and uses thereof
US20050260749A1 (en) 2004-04-01 2005-11-24 Jon Odorico Differentiation of stem cells to endoderm and pancreatic lineage
US20070142376A1 (en) 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
US20090186076A1 (en) 2006-02-01 2009-07-23 Kazunori Kataoka Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent
US8247531B2 (en) 2006-03-20 2012-08-21 Cochran Jennifer R Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
US20080269206A1 (en) 2007-04-02 2008-10-30 Institute For Oneworld Health Cftr inhibitor compounds and uses thereof
WO2008121877A2 (en) 2007-04-02 2008-10-09 Institute For Oneworld Health Cftr inhibitor compounds and uses thereof
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
US20100267731A1 (en) 2009-04-17 2010-10-21 Summa Health Systems, LLC Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000084A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013052700A1 (en) 2011-10-04 2013-04-11 The Brigham And Women's Hospital, Inc. Novel sulfonamides
WO2013071282A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
WO2013169576A1 (en) 2012-05-08 2013-11-14 Merck Sharp & Dohme Corp. Permeable glycosidase inhibitors and uses thereof
WO2013166654A1 (en) 2012-05-08 2013-11-14 Merck Sharp & Dohme Corp. Permeable glycosidase inhibitors and uses thereof

Non-Patent Citations (133)

* Cited by examiner, † Cited by third party
Title
Aguayo-Mazzucato, C, Zavacki, AM, Marinelarena, A., Hollister-Lock, J., Khattabi, IE, Marsili, A., Weir, GC, Sharma, A., Larsen, PR und Bonner- Weir, S . (2013
Altschul et al. Nucleic Acids Res. 25: 3389-3402, 1997
Altschul, et al., J. Mol. Biol. 215: 403-410, 1990
Atlas of Clinical Endocrinology Vol. 2
Ausgaben Molecular Cloning: A Laboratory Manual, (Sambrook et al., Cold Spring Harb
Ausubel, F., et al, (Hrsg.), Current Protocols in Molecular Biology, Current Protocols in Immunology, Current Protocols in Protein Science und Current Protocols:. Nicht einschränkende Beschreibungen bestimmter dieser Techniken sind in den folgenden Veröffentlichungen in Cell Biology, alle John Wiley & Sons, NY, Ausgabe vom Dezember 2008
Banting et al, Can. Med. Assoc. J. 22: 141, 1922
Bellin, MD, Barton, FB, Heitman, A., Harmon, J., Balamurugan, AN, Kandaswamy, R., Sutherland, DE, Alejandro, R., und Hering, BJ (2012). Potent Induction Immuntherapie Fördert die Langzeit-Insulin Unabhängigkeit Nach Islet Transplantation in Typ 1 Diabetes. American Journal of Transplantation 12, 1576-583
Bhattacharya (2004) Blut 103 (8): 2956- 64
Bicknese et al, 2002 Cell Transplantation 1 1: 261 -264
Bongso et al, Hum Reprod. 4: 706, 1989
Boretti und Gooch (Tissue Eng. 2006 April; 12 (4): 939-48
Brelje, TC, Stout, LE, Bhagroo, NV, und Sorenson, RL (2004). Scheidungs Rollen für Prolaktin und Wachstumshormon bei der Aktivierung der Signalwandler und Aktivator der Transkription 5 in pankreatischen Langerhansschen Inseln. Endocrinology 145, 4162- 175
Broxmeyer 1995 Transfusion 35: 694-702
Broxmeyer et al., 1992 Proc. Natl. Acad Sci. USA 89: 4109-41 13
Broxmeyer et al., 1992 Proc. Natl. Acad. Sci. USA 89: 4109-41 13
Cell Stem Cell 10, 371 -384
Chatzigeorgiou A, et al., In Vivo. 2009 März-Apri 1; 23 (2): 245-58
Chen et al 2001 Stroke. 32: 2682-2688
Chen et al unterstützen identifizieren können., 2006
Cheng, X., Ying, L., Lu, L., Galvao, AM, Mills, JA, Lin, HC, Kotton, DN, Shen, SS, Nostro, MC, et al. (2012
Cowan et al. (N Engl. J. Med. 350: 1 353, 2004
Cowan et al. (N Engl. J. Med. 350: 1353 2004
CR Kahn et al. eds, Blackwell Science. 1999
Curr. Top. Dev. Biol. 38: 133 ff, 1998
Current Protocols in Immunologie (JE Colligan et al., Hrsg., Wiley & Sons
Current Protocols in Molecular Biology (FM Ausubel et al., Hrsg., Wiley & Sons
Current Protocols in Protein Science (JE Colligan et al eds, Wiley & Sons
Current Protocols in Zellbiologie (JS Bonifacino et al., Wiley & Sons
D. Leroith ed, Lippincott Raven 2000
D'Amour, KA, Agulnick, AD, Eliazer, S., Kelly, OG, Kroon, E., und Baetge, EE (2005). Effiziente Differenzierung von humanen embryonalen Stammzellen, endgültige Endoderm. Nat Biotechnol 23, 1 534-541
D'Amour, KA, Bang, AG, Eliazer, S., Kelly, OG, Agulnick, AD, Elegante Kleidung, NG, Moorman, MA, Kroon, E., Carpenter, MK und Baetge, EE (2006). Produktion von Pankreashormon exprimierende endokrinen Zellen aus menschlichen embryonalen Stammzellen. Nat Biotechnol 24, 1392- 1401
Danos et al (. 1988) PNAS 85: 6460-6464
Ding, Q., Lee, Y.-K., Schaefer, EK, Peters, D., Veres, A., Kim, K., Kuperwasser, N., Motola, D., Meissner, T., et al. (2013). Ein TALEN Genom-Editing System zur Erzeugung von menschlichen Stammzell-basierte Krankheitsmodelle. Cell Stem Cell 12, 238-251
Eisenberg & Bader (1996) Circ Res. 78 (2): 205- 16
Erices et al., 2000 Br. J. Hämatologie 109: 235-242
Fetal Islet Transplantation, von CM Peterson et al. Hrsg., Kluwer 1995
Freshney, RI, „Culture of Animal Cells, ein Handbuch der Grundtechnik", 5. Aufl., John Wiley & Sons, Hoboken, NJ 2005
G. Morstyn & W. Sheridan eds, Cambridge University Press, 1996; und Blutstammzell-Therapie, ED Ball, J. Lister & P. Recht, Churchill Livingstone, 2000
Gardner et al., Fertil. Steril. 69:84, 1998
Gentransfervektoren für Säugetierzellen (Miller & Calos eds
Goodman und Gilman ist die pharmakologische Basis of Therapeutics Treffer 1 1 th Ed., McGraw Hill, 2005 Katzung, B. (Hrsg. ) Basic and Clinical Pharmacology, McGraw-Hill / Appleton & Lange
Harlow, E. und Lane, D., Antibodies - A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1988
Hernandez et al, „Mikrokapseln und Mikroträger für die In-situ-Zelle Lieferung", Advanced Drug Delivery Reviews 2010; 62: 71 1-730
Hrvatin, S "O'Donnell, CW, Deng, F., Millman, J. R., Pagliuca, FW, Dilorio, P., Rezania, A., Gifford, DK und Melton, DA (2014). Differenzierten humanen Stammzellen ähneln fetalen, nicht für Erwachsene, β-Zellen. Proc Natl Acad Sci USA, 201.400.709
Ito et al., Environ. Toxicol. Pharmacol. 9:71, 2001
J. Endocrinol. 158: 49, 2001
J. Pathol. 105: 194, 1981
Johns Hopkins University Press, 1 98
Kador et al, Arch.. Opthalmol. 1 13: 352, 1995
Karlin und Altschul, Proc modifiziert. Natl. Acad. ScL USA 90: 5873-5877, 1993
Karlin und Altschul, Proc. Natl. Acad. Sci. USA 87: 22264-2268, 1990
Keirstead, HS, Nistor, G., Bernal, G., Totoiu, M., Cloutier, F., Sharp, K., und Steward, O. (2005). Menschliche embryonale Stammzellen abgeleiteten Oligodendrozyten-Vorläuferzell-Transplantationen remyelinate und Wiederherstellungsfortbewegung nach Verletzungen des Rückenmarks. Journal of Neuroscience 25, 4694-4705
Kohli-Kumar et al., 1993 Br. J. Haematol. 85: 419-422
Kriks, S., Shim, J.-W., Piao, J., Ganat, YM, Wakeman, DR, Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C und Buch, A. (201 1). Dopamin-Neuronen aus menschlichen ES-Zellen abgeleitet effizient engraft in Tiermodellen der Parkinson / Krankheit. Nature 480, 547-551
Kroon, E., Martinson, LA, Kadoya, K., Bang, AG, Kelly, OG, Eliazer, S., Junge, H., Richardson, M., Elegante Kleidung, NG, et al. (2008). Pankreatischen Endoderms aus menschlichen embryonalen Stammzellen erzeugt auf Glucose reagierenden insulinsezernierenden Zellen in vivo. Nat Biotechnol 26, 443-452
L. Rosenberg et al, Chapman & Hall. 1999
Labriola, L., Montor, WR, Krogh,., Lojudice, FH, Genzini, T., Goldberg, AC, Eliaschewitz, FG und Sogayar, MC (2007
Lammert, E., Cleaver, O., und Melton, D. (2001). Induktion von Pankreasdifferenzierung durch Signale von Blutgefäßen. Science 294, 564-67
Lenzen et al. (Diabetologia 44: 1 1 89, 2001
Lewis, Hrsg. „Controlled Release von Pestiziden und Pharma" (Plenum Press, New York, 1981
Lopez el ah, „Staurosporin abgeleiteten Inhibitoren erweitern den Anwendungsbereich der Analogsensitive Kinase Technologie", J. Am. Ckern. Soc. 2013; 135 (48): 18.153 bis 18.159
Lu et al 1995 Cell Transplantation 4: 493-503
Lu et al., 1993, J. Exp Med. 178: 2089-2096
Lu et al., 1996 Crit. Rev. Oncol. Hematol 22:61 -78
Lu, B., Malcuit, C, Wang, S., Girman, S., Francis, P., Lemieux, L., Lanza, R., und Lund, R. (2009). Langfristige Sicherheit und Funktion des RPE aus menschlichen embryonalen Stammzellen in präklinischen Modellen der Makula-Degeneration. Stem Cells 27, 2126- 135
M iller et al, (1985) Mol, Cell Biol, 5.43 1 -437
Manual of Basic-Technique (RI Freshney ed, Wiley & Sons
Matschinsky, F.M. (2009). Bewertung der Möglichkeiten Glukokinaseaktivatoren in der Diabetestherapie. Nature Reviews Drug Discovery 8, 399-416
McCall, M, und Shapiro, A.M.J. (2012). Aktualisieren Sie auf Islet Transplantation. Cold Spring Harb Perspect Med 2, a007823
Medical Management von Typ 1 Diabetes 3rd Edition, McGraw Hill 1 98
Methoden und Protokolle (K. Turksen ed, Humana Press
Miller et al. (1 86), Mol. Gen. Zelle. Biol. 6: 2895-2902
Modi, P. (2007). Diabetes über Insulin: Bewertung von neuen Medikamenten für die Behandlung von Diabetes mellitus. Curr Drug Discov Technol 4, 39-47
Mohammed, JS, Wang, Y., Harvat, TA, Oberholzer, J., und Eddington, DT (2009). Mikrofluidik-Vorrichtung für multimodale Charakterisierung der Langerhans-Inseln. Lab Chip 9, 97- 106
Mol Cell Endocrinol 263, 120- 133
Muanprasat et al., „Discovery of Glyciine Hydrazide Poren- Okklusionsbauteil CFTR Inhibitors", J. Gen. Physiol 2004; 124 (2): 125-137
Murua et al, „Zell Mikroverkapselung: Auf dem Weg zu klinischen Anwendung"., Journal of Controlled Release 2008; 132: 76-83
Narayanan,., Lim, VY, Shen, J., Bräune, ZW, Rajendran, D., Luo, SC, Gao, S., Wan, CA, und Ying, J. (2013). Extrazellulären Matrix-vermittelten Differenzierung menschlicher embryonaler Stammzellen: Differenzierung zu Insulin sekretierenden Betazellen. Tissue Eng Teil A 20, 424-433
Negrin et al, Biomaterials, 22 (6): 563 (2001
Nieda et al., 1997 Br. J. Hämatologie 98: 775- 777
Nohe et al Zellsignal. 16: 291 -299, 2004
Nostro, MC, Sarangi, F., Ogawa, 8 „Holtzinger, A., Corneo, B., Li, X., Micallef, SJ, Park, IH, Basford, C, et al. (201 1). Stufenspezifischen Signalisierung durch TGF {beta} Familienmitglieder und WNT regelt Strukturierung und Bauchspeicheldrüsen Spezifikation der menschlichen pluripotenten Stammzellen. Entwicklung 138, 861 -871
Online Mendelian Inheritance in Man, OMIM ™. McKusick- Nathans Institut für Genetische Medizin, Johns Hopkins University
Orive et al., „Anwendung der Verkapselung von Zellen zur kontrollierten Abgabe von biologischen Therapeutika", Advanced Drug Delivery Reviews (2013
Parsons, JA, Brelje, TC und Sorenson, RL (1992). Anpassung der Langerhans-Inseln, um eine Schwangerschaft: erhöhte Inselzellproliferation und Insulinsekretion korreliert mit dem Auftreten von Plazentalaktogen Sekretion. Endocrinology 130, 1459-466
Pear et al. (1993) P.N.A.S. 90: 8392-8396
Pearson, T., Greiner, D. L. und Shultz, L. D. (2008). Schaffung von „humanisierten" Mäusen, die menschliche Immunität zu studieren. Curr Protoc Immunol Kapitel 15, Einheit 15.21
Rees et al, Diabet Med. 2005 April; 22 (4): 359-70
Reubinoff et al, Nature Biotech.. 18: 399, 2000
Reyes et al. ( 2001) Blut 98: 2615-2625
Rezania, A., Bruin, J. E., Xu, J., Narayan, K ... Fox, J. K., O'Neil, J. J. und Kieffer, T. J. (2013). Anreicherung von menschlichen embryonalen Stammzellen abgeleiteten N X6-1 exprimierenden Pankreas-Vorläuferzellen beschleunigt die Reifung von insulinsezernierenden Zellen in vivo. Stem Cells 31, 2432-442
Rezania, A., Bruin, JE, Riedel, MJ, Mojibian, M., Asadi, A., Xu, J., Gauvin, R., Narayan, K., Karanu, F., et al. (2012). Reifung von humanen embryonalen Stammzell- Abgeleitet Bauchspeicheldrüsen Vorläufern in funktionale Inseln Fähig zur Behandlung Bereits bestehende Diabetes bei Mäusen. Diabetes 61, 2016-029
Rodriguez-Diaz, R., Dando, R., Jacques-Silva, MC, Fachado, A., Molina, J „Abdulreda, MH, Ricordi, C, Roper, SD, Berggren, PO, und Caicedo, A. (201 1). Alpha-Zellen sezer Acetylcholin als nichtneuronalen parakrinen Signals Priming Beta-Zellfunktion bei Menschen. Nat Med 17, 888-892
Rutter, G. A. und Hodson, D. J. (2013). Kurzaufsatz: Intraislet Verordnung der Insulin-Sekretion beim Menschen. Molecular Endocrinology 27, 1984-995
Sambrook, Russell, und Sambrook, Molecular Cloning:. A Laboratory Manual, 3. Auflage, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2001
Sanchez -. Ramos et al 2001 Exp. Neur. 171: 109- 1 15
Schilddrüsenhormon fördert Postnatale Rattenpankreas β-Zellentwicklung und Glucose-Responsive Insulinsekretion Durch MAFA. Diabetes 62, 1569-580
Schulz, TC, Lynn, FC, Jung, HY, Agulnick, AD, Babin, MJ, Baetge, EE, Bang, AG, Bhoumik, A., Cepa, I., et al. (2012). Ein skalierbares System für die Herstellung von Funktionsbauchspeicheldrüsen Vorläufern von humanen embryonalen Stammzellen. PLoS ONE 7, e37004
Schumacher, et al., Mol. Zelle. Neurosci. 2003; 23 (4): 669-680
Sebald et al. Biol. Chem. 385: 697-710, 2004
Shambloft et al., Proc. Natl. Acad. Sci. USA 95: 13726, 1998
Shamblott et al., Proc. Natl. Acad. Sci. USA 95: 13726, 1998
Shapiro, AM, Ricordi, C, Hering, BJ, Auchincloss, H., Lindblad, R., Robertson, RP, Secchi, A., Brendel, MD, Berney, T., et al. (2006). Internationalen Verfahrens gegen die Edmonton-Protokoll für Inseltransplantation. N Engl J Med 355, 131 8-330
Shiba, Y., Fernandes, S., Zhu, WZ, Filice, D., Muskheli, V., Kim, J., Palpant, NJ, Gantz, J., Moyes, KW und Reinecke, H. (2012) . Menschlichen ES-Zellen abgeleiteten Kardiomyozyten elektrisch zu koppeln und Arrhythmien in verletzten Herzen zu unterdrücken. Nature 489, 322-25
Sneddon, J. B., Borowiak, M., und Melton, D. A. (2012). Selbsterneuerung embryonaler Stamm--Zellen abgeleiteten Vorläuferzellen durch organ abgestimmt Mesenchym. Nature 491, 765-68
Solter et al., Proc. Natl. Acad. Sci. USA 72: 5099, 1975
Soria et al, Diabetes. 49: 1 57, 2000
Srinivasan K, et al., J Indian Med. Res. 2007 März; 125 (3): 451 -7
Taylor & Bryson, 1985J. Immunol ist. 134: 1493- 1497
Taylor & Bryson, 1985J. Immunol. 134: 1493- 1497
Taylor, B. L., Liu, SV- und Sander, M. (2013). NKX6- 1 Grundbaustein für den Funktionszustand des pankreatischen Betazellen. Zell Rep 4, 1262-275
Techniken der Zellkultur (MA Harrison & IF Rae, Cambridge Univ. Press
Thomson et al veranschaulicht. ( 1998) Science 282: 1 145
Thomson et al, Science 282:. 1 145, 1998
Thomson et al. ( 1996) Biol. Reprod, 55: 254
Thomson et al. ( Science 282: 1 145, 1998
Thomson et al. (1995) Proc. Natl. Acad. Sci. USA 92: 7844
Thomson et al. Biol. Reprod. 55: 254, 1996
Thomson et al., Proc. Natl. Acad. Sci. USA 92: 7844, 1995
Thowfeequ, S., Ralphs, KL, Yu, W.-, Slack, JMW und Tosh, D. (2007). Betacellulin hemmt Amylase und Glucagon Produktion und fördert die Beta-Zell-Differenzierung in embryonalen Maus-Pankreas. Diabetologia 50, 1688-697
Tremml et al. ( Curr Protoc Stem Cell Biol. Kapitel 1: Einheit 1 C.4, 2008
Urquhart et al., Ann. Rev. Pharmacol. Toxicol. 24: 199-236 (1984
Vetere, A., Choudhary, A., Burns, SM, und Wagner, BK (2014). Targeting der pankreatischen β-Zellen zur Behandlung von Diabetes. Nature Reviews Drug Discovery Xie, R „Everett, LJ, Lim, HW, Patel, NA, Schug, J., Kroon, E., Kelly, OG, Wang, A., D'Amour, KA, et al. (2013). Dynamische Chromatin-Remodeling-vermittelte durch Polycomb Proteine orchestriert Bauchspeicheldrüsen Differenzierung von humanen embryonalen Stammzellen. Cell Stem Cell 12, 224-237
Wagner et al 1992, Blut 79. 1874- 1881
Watanabe, K. et al, Nature Biotechnology 25, 681 -. 686 (2007
WN Kelley ed, Lippincott-Raven., 1997
Wong et al., Immunol. Rev. 169: 93, 1999
Xu et al., Nat. Biotechnol. 19: 971 2001
Yoshida et al., Rev. Immunogenet. 2: 140, 2000
Zanin et al, „Die Entwicklung von eingekapselten Zelltechnologien wie Therapien für neurologische und sensorische Erkrankungen", Journal of Controlled Release 2012. 160: 3-13
zB Jahansouz et al, „Evolution of / 3-Zellersatztherapie bei Diabetes mellitus: die Inselzelltransplantation". Journal of Transplantation 201 1, Volume 201 1, Artikel-ID 247959
Zhang et al., Diabetes beschrieben. 50 (10): 2231 6 (2001

Also Published As

Publication number Publication date
SG11201510177WA (en) 2016-01-28
KR20220106230A (ko) 2022-07-28
DK3008168T3 (da) 2020-05-04
EP4461806A3 (en) 2025-02-12
US20170029778A1 (en) 2017-02-02
RU2016100433A (ru) 2017-07-17
JP2025063288A (ja) 2025-04-15
US11078463B2 (en) 2021-08-03
KR102205234B1 (ko) 2021-01-20
US11162078B2 (en) 2021-11-02
KR102423106B1 (ko) 2022-07-21
GB2549822B (en) 2018-05-02
GB2549822A (en) 2017-11-01
WO2014201167A1 (en) 2014-12-18
KR102390167B1 (ko) 2022-04-25
CN105579577A (zh) 2016-05-11
KR102631225B1 (ko) 2024-01-31
JP2023093654A (ja) 2023-07-04
JP2019141072A (ja) 2019-08-29
US12054745B2 (en) 2024-08-06
AU2020289721A1 (en) 2021-01-21
US11827905B2 (en) 2023-11-28
JP7354026B2 (ja) 2023-10-02
GB2557508A9 (en) 2018-09-05
EP3008170A4 (en) 2016-11-09
BR112015030946A8 (pt) 2020-01-28
AU2014278178A1 (en) 2016-01-28
US20150240212A1 (en) 2015-08-27
US20250019661A1 (en) 2025-01-16
US20190017031A1 (en) 2019-01-17
JP6514689B2 (ja) 2019-05-15
WO2015002724A4 (en) 2015-03-26
SG11201510176VA (en) 2016-03-30
AU2023237028B2 (en) 2026-01-08
US20200385681A1 (en) 2020-12-10
JP2016531087A (ja) 2016-10-06
AU2026202516A1 (en) 2026-04-23
CN106414718A (zh) 2017-02-15
BR112015030946A2 (pt) 2017-07-25
US20240124847A1 (en) 2024-04-18
US10030229B2 (en) 2018-07-24
DE112014002780B4 (de) 2025-05-22
AU2020203127C1 (en) 2023-12-21
EP3008168B1 (en) 2020-02-19
EP3008170A1 (en) 2016-04-20
EP3008168A2 (en) 2016-04-20
KR102523912B1 (ko) 2023-04-21
HK1257187B (zh) 2020-06-12
GB2557508B (en) 2018-11-07
US20150218522A1 (en) 2015-08-06
CN121427797A (zh) 2026-01-30
KR20230135180A (ko) 2023-09-22
MX2019003616A (es) 2019-08-01
KR102341674B1 (ko) 2021-12-22
BR112015030972A2 (pt) 2017-07-25
RU2016100219A3 (https=) 2018-03-30
KR20230054767A (ko) 2023-04-25
US20220162562A1 (en) 2022-05-26
AU2020203127B2 (en) 2023-06-22
KR102361924B1 (ko) 2022-02-14
CN110551678A (zh) 2019-12-10
KR20210008926A (ko) 2021-01-25
AU2020203127A1 (en) 2020-06-04
SG10201710218RA (en) 2018-01-30
CN110551678B (zh) 2024-02-20
US20210079355A1 (en) 2021-03-18
JP2016532436A (ja) 2016-10-20
AU2014284677B2 (en) 2020-03-12
DE112014002780T5 (de) 2016-06-23
AU2014278178B2 (en) 2021-01-21
GB2531952A (en) 2016-05-04
KR20220051442A (ko) 2022-04-26
JP7766641B2 (ja) 2025-11-10
RU2016100219A (ru) 2017-07-17
KR20210156337A (ko) 2021-12-24
KR102580225B1 (ko) 2023-09-20
CA2915091A1 (en) 2014-12-18
WO2015002724A2 (en) 2015-01-08
US20190169575A1 (en) 2019-06-06
RU2019108582A3 (https=) 2021-08-04
EP3008168A4 (en) 2017-05-31
EP3569694A1 (en) 2019-11-20
KR20220025151A (ko) 2022-03-03
MX2015017103A (es) 2016-11-07
AU2020289721B2 (en) 2023-09-14
US20230076529A1 (en) 2023-03-09
KR20200143750A (ko) 2020-12-24
KR102232650B1 (ko) 2021-03-29
WO2015002724A3 (en) 2015-02-26
JP6677634B2 (ja) 2020-04-08
WO2014201167A4 (en) 2015-01-29
US20240101963A1 (en) 2024-03-28
KR20240014630A (ko) 2024-02-01
US10655106B2 (en) 2020-05-19
AU2014284677A1 (en) 2016-02-25
JP2020108394A (ja) 2020-07-16
KR102640729B1 (ko) 2024-02-27
KR102773841B1 (ko) 2025-02-27
AU2023229504A1 (en) 2023-09-28
KR20160034892A (ko) 2016-03-30
BR112015030972A8 (pt) 2020-01-28
PH12015502767A1 (en) 2016-03-21
KR102201638B1 (ko) 2021-01-13
RU2692595C2 (ru) 2019-06-25
GB201803318D0 (en) 2018-04-18
KR20210034688A (ko) 2021-03-30
GB2531952B (en) 2017-02-08
JP2021121223A (ja) 2021-08-26
US12049646B2 (en) 2024-07-30
EP4461806A2 (en) 2024-11-13
RU2019108582A (ru) 2019-07-05
JP6893527B2 (ja) 2021-06-23
US20250043247A1 (en) 2025-02-06
US20190040362A1 (en) 2019-02-07
KR20160099079A (ko) 2016-08-19
JP2024054254A (ja) 2024-04-16
US20200347358A1 (en) 2020-11-05
CN112226402A (zh) 2021-01-15
US11104883B2 (en) 2021-08-31
GB2557508A (en) 2018-06-20
GB201521857D0 (en) 2016-01-27
GB201622354D0 (en) 2017-02-15
US20220396775A1 (en) 2022-12-15
CN120796168A (zh) 2025-10-17
CA2915088A1 (en) 2015-01-08
GB2531952C (en) 2019-10-09
AU2023237028A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
US12049646B2 (en) SC-beta cells and compositions and methods for generating the same
HK40118588A (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME

Legal Events

Date Code Title Description
R150 Utility model maintained after payment of first maintenance fee after three years
R079 Amendment of ipc main class

Free format text: PREVIOUS MAIN CLASS: C12N0005071000

Ipc: A61K0035390000

R150 Utility model maintained after payment of first maintenance fee after three years
R207 Utility model specification
R082 Change of representative

Representative=s name: STRAUS, ALEXANDER, DIPL.-CHEM.UNIV. DR.PHIL., DE

Representative=s name: 2K PATENT- UND RECHTSANWAELTE PARTNERSCHAFT MB, DE

R151 Utility model maintained after payment of second maintenance fee after six years
R152 Utility model maintained after payment of third maintenance fee after eight years
R071 Expiry of right
R082 Change of representative

Representative=s name: STRAUS, ALEXANDER, DIPL.-CHEM.UNIV. DR.PHIL., DE